Trial Profile
A Phase I/II Trial of IDEC-114 (Anti-CD80 Monoclonal Antibody) in Combination With Rituxan? for Patients With Relapsed or Refractory, Follicular Lymphoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Galiximab (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 23 Jun 2009 Planned end date (Dec 2013) added as reported by ClinicalTrials.gov.
- 23 Jun 2009 Planned end date (Dec 2013) added as reported by ClinicalTrials.gov.
- 16 Jun 2009 Planned number of patients changed from 39 to 90 as reported by ClinicalTrials.gov.